These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3389081)

  • 1. Myasthenia gravis treated with ciclosporin.
    Nyberg-Hansen R; Gjerstad L
    Acta Neurol Scand; 1988 Apr; 77(4):307-13. PubMed ID: 3389081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis.
    Goulon M; Elkharrat D; Lokiec F; Gajdos P
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):211-7. PubMed ID: 3260050
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of severe myasthenia gravis with cyclosporin. A 12-month open trial].
    Goulon M; Elkharrat D; Gajdos P
    Presse Med; 1989 Feb; 18(7):341-6. PubMed ID: 2522627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of an open trial of cyclosporine in a group of steroido-dependent myasthenic subjects.
    Antonini G; Bove R; Filippini C; Millefiorini M
    Clin Neurol Neurosurg; 1990; 92(4):317-21. PubMed ID: 1963821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
    Palace J; Newsom-Davis J; Lecky B
    Neurology; 1998 Jun; 50(6):1778-83. PubMed ID: 9633727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Titer of anti-muscle-specific receptor tyrosine kinase (MuSK) antibody correlated with symptomatic improvement in response to corticosteroid therapy in a patient with anti-MuSK antibody-positive myasthenia gravis: a case report].
    Nakahama Y; Kawajiri M; Ochi M; Kohara K; Ohta K; Miki T
    Rinsho Shinkeigaku; 2007 Jun; 47(6):356-8. PubMed ID: 17633110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciclosporin in the treatment of myasthenia gravis.
    Tindall RS; Phillips JT; Rollins JA; Greenlee RG; Wells L; Belendiuk G
    Monogr Allergy; 1988; 25():135-47. PubMed ID: 3173362
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunosuppressive agents for myasthenia gravis.
    Hart IK; Sathasivam S; Sharshar T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone density in myasthenia gravis patients receiving long-term prednisolone therapy.
    Wakata N; Nemoto H; Sugimoto H; Nomoto N; Konno S; Hayashi N; Araki Y; Nakazato A
    Clin Neurol Neurosurg; 2004 Mar; 106(2):139-41. PubMed ID: 15003307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ocular involvement in MuSK antibody-positive myasthenia gravis].
    Bau V; Hanisch F; Hain B; Zierz S
    Klin Monbl Augenheilkd; 2006 Jan; 223(1):81-3. PubMed ID: 16418940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
    Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
    N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoadsorption therapy for myasthenia gravis.
    Shibuya N; Sato T; Osame M; Takegami T; Doi S; Kawanami S
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):578-81. PubMed ID: 8201327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].
    Hayashi R; Tahara M; Oeda T; Konishi T; Sawada H
    Rinsho Shinkeigaku; 2015; 55(4):227-32. PubMed ID: 25904250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-acetylcholine receptor antibodies: effect of immunosuppressive drug therapy in patients with myasthenia gravis].
    Sidnev DV; Sanadze AG; Dedaev SI; Karganov MIu; Alchinova IB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 1):37-40. PubMed ID: 21183922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pemphigus vulgaris with cyclosporine.
    Bondesson L; Hammar H
    Dermatologica; 1990; 181(4):308-10. PubMed ID: 2073961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
    J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Amount of circulating acetylcholine receptor antibodies in the course of myasthenia, following thymectomy and in immunosuppressive therapy].
    Patzold U; Kalies I; Haas J; Ginda EM
    Nervenarzt; 1984 Aug; 55(8):426-31. PubMed ID: 6483064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.